Table 3.
Comparison of children with PIMS-TS needing PICU care and no PICU care.
| PIMS-TS admitted to PICU n = 23 | PIMS-TSNo PICU n = 21 | p value | |
|---|---|---|---|
| Age | 7.2y (11 m – 16 y) | 5y (6 m – 13 y) | 0.116 |
| Male | 11 (37%) | 14 (56%) | 0.16 |
| Clinical features n (%) | |||
| Fever | 23 (100%) | 21 (100%) | |
| Gastrointestinal symptoms | 18 (78%) | 19 (90%) | 0.2 |
| Mucocutaneous symptoms | 17 (74%) | 17 (81%) | 0.5 |
| Respiratory symptoms | 9 (39%) | 2 (9%) | 0.006 |
| Hypotension | 23 (100%) | 0 | <0.00001 |
| Shock (vasodilated) | 18 (78%) | 3* (14%) | <0.00001 |
| ECHO at PICU admission (n) | |||
| Coronary artery dilatation | 2 | 0 | |
| Myocardial dysfunction | 23 | 0 | <0.00001 |
| Respiratory support (n) | |||
| Nasal cannula oxygen | 1 | 6 | |
| HHFNC | 2 | 0 | |
| Mechanical ventilation | 0 | 0 | |
| Cardiovascular support (n) | |||
| Fluid bolus | 21 (91%) | 3 (14%) | |
| Vasoactive support | 19 (83%) | 0 | |
| Adrenaline | 7 | ||
| Nor-adrenaline | 19 | ||
| Medications n (%) | |||
| IVIG | 23 (100%) | 14 (66%) | |
| Steroids | 23 (100%) | 9 (43%) | |
| Immunomodulatory agent# | 1 | 1 | |
| Aspirin | 17 (75%) | 0 | |
| Antibiotics | 23 (100%) | 21 (100%) | |
| Gastro protective agents | 23 (100%) | 21 (100%) | |
| Laboratory parameters | |||
| CRP (<5 mg/L) | 177 (37.5 - 298) | 137 (9 – 370) | 0.34 |
|
D-Dimer (ng/ml FEU) (100–500) median (IQR) |
4890 (2446 – 10,000) | 3718 (117 – 10,000) | 0.03 |
|
Lymphocyte(/mm3) (1500 – 4000) median (IQR) |
1386 (330 – 4540) | 2023 (880 – 6460) | 0.13 |
|
Neutrophils (/mm3) (1500 – 7000) median (IQR) |
7800 (3360 – 14,180) | 9500 (2700 – 34,000) | 0.08 |
| Sodium (135–145 mmol/l) median (IQR) | 133 (130 – 136) | 133 (127 −143) | 0.44 |
|
Ferritin (ng/mL) (7 to 140) median (IQR) |
605 (38 −2571) | 247 (101 – 1104) | 0.006 |
|
LDH (U/L) (125–243) median (IQR) |
494 (200 −905) | 487 (264 −928) | 0.3 |
⁎
3 children required fluid bolus at ER.
#
Immunomodulatory drug – Tocilizumab.